Abstract 127P
Background
There is no widely used prognostic tool to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC). We aimed to establish the prognostic score and demonstrate the real-world efficacy of FOLFOX4 in Thai patients.
Methods
Between August 2017 and December 2021, 58 patients with HCC treated with FOLFOX4 were identified. Efficacies of FOLFOX4, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were assessed. The prognostic score was constructed by stepwise cox proportional hazards regression combined with clinical experience to select variables for the best model.
Results
44 patients (76%) received FOLFOX4 as first-line systemic therapy. The efficacies of FOLFOX4 in the entire cohort were ORR of 8.6% and clinical benefit rate (CBR) of 29.3%. The median OS and PFS were 4.8 and 3.7 months, respectively. Four variables were included in the new prognostic score to predict 6-month overall survival based on their clinical relevance: L, the presence of lung metastasis; A, alcoholic cirrhosis; B, elevated total bilirubin; and S, sorafenib naive. The new prognostic "LABS" score classified all patients into low-, intermediate-, and high-risk groups, demonstrating the median OS of 9.3, 4.2, and 2.1 months, respectively (P<0.0001). The C-index and area under receiver operating characteristic curve of this score were 0.71 and 0.73, respectively.
Conclusions
The FOLFOX4 regimen showed comparable ORR, PFS, and OS efficacy to previous reports. The proposed prognostic “LABS” score clearly discriminated patients who would have the benefit from FOLFOX4. Therefore, we suggest that FOLFOX4 should be considered as one of the options for those who cannot approach immunotherapy and targeted therapy, particularly with a low-risk score. However, this model should be further evaluated in the larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02